Your browser doesn't support javascript.
loading
ALSUntangled #75: Portable neuromodulation stimulator therapy.
Officer, Laurel; Armon, Carmel; Barkhaus, Paul; Beauchamp, Morgan; Benatar, Michael; Bertorini, Tulio; Bowser, Robert; Bromberg, Mark; Brown, Andrew; Carbunar, Olimpia Mihaela; Carter, Gregory T; Crayle, Jesse; Denson, Keelie; Feldman, Eva; Fullam, Timothy; Heiman-Patterson, Terry; Jackson, Carlayne; Jhooty, Sartaj; Levinson, Danelle; Li, Xiaoyan; Linares, Alexandra; Mallon, Elise; Mascias Cadavid, Javier; Mcdermott, Christopher; Mushannen, Tasnim; Ostrow, Lyle; Patel, Ronak; Pattee, Gary; Ratner, Dylan; Sun, Yuyao; Sladky, John; Wicks, Paul; Bedlack, Richard.
Afiliación
  • Officer L; Department of Neurology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Armon C; Department of Neurology, Shamir Medical Center, Tzrifin, Israel.
  • Barkhaus P; Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Beauchamp M; UNC Neuroscience Clinical Trials Unit, Chapel Hill, NC, USA.
  • Benatar M; Department of Neurology, University of Miami, Miami, FL, USA.
  • Bertorini T; Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Bowser R; Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Bromberg M; Department of Neurology, University of Utah, Salt Lake City, UT, USA.
  • Brown A; Department of Neurology, University of Miami, Miami, FL, USA.
  • Carbunar OM; Department of Neurology, University of Miami, Miami, FL, USA.
  • Carter GT; Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
  • Crayle J; Department of Neurology, Washington University, St. Louis, MO, USA.
  • Denson K; Department of Neurology, Houston Methodist Hospital, Houston, TX, USA.
  • Feldman E; Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  • Fullam T; Department of Neurology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Heiman-Patterson T; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Jackson C; Department of Neurology, UT Health San Antonio, San Antonio, Texas, USA.
  • Jhooty S; Department of Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Levinson D; Medical School, Duke University, Durham, NC, USA.
  • Li X; Department of Neurology, Duke University, Durham, NC, USA.
  • Linares A; Medical School, Duke University, Durham, NC, USA.
  • Mallon E; Undergraduate, Duke University, Durham, NC, USA.
  • Mascias Cadavid J; ALS Unit, Neurology Department, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Mcdermott C; Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK.
  • Mushannen T; Department of Neurology, Duke University, Durham, NC, USA.
  • Ostrow L; Department of Neurology, Temple Health, Philadelphia, PA, USA.
  • Patel R; Department of Neurology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Pattee G; Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Ratner D; Undergraduate, Tulane University, New Orleans, LA, USA.
  • Sun Y; Department of Neurology, University of Kentucky, Lexington, KY, USA, and.
  • Sladky J; Department of Neurology, Brooke Army Medical Center, San Antonio, TX, USA.
  • Wicks P; Independent Consultant, Lichfield, England, UK.
  • Bedlack R; Department of Neurology, Duke University, Durham, NC, USA.
Amyotroph Lateral Scler Frontotemporal Degener ; : 1-5, 2024 Apr 26.
Article en En | MEDLINE | ID: mdl-38666601
ABSTRACT
Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Amyotroph Lateral Scler Frontotemporal Degener Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos